LB Pharmaceuticals reports a deeper-than-expected Q2 loss, with cash reserves projected to fund operations beyond mid-2029.
LB Pharmaceuticals Inc posted a Q2 GAAP loss per share of $1.71, missing estimates by $0.90. The wider-than-anticipated loss reflects ongoing R&D investments and operational costs.
Cash reserves stood at $327.8 million as of June 30, 2026, excluding $150.0 million from a July private placement. Analysts had expected a narrower loss, though the company’s liquidity position remains robust.
Management stated current cash reserves should sustain operations beyond the second quarter of 2029, easing near-term funding concerns.